Breast cancer in mice: effect of murine MUC-1 immunization on tumor incidence in C3H/HeOuj mice.
Mucin-1 (MUC-1), which is overexpressed in more than 90% of human breast cancers, is a potential target for immunotherapy. To develop a mouse model appropriate for the immunotherapy of human cancer, mouse mucin-1 (muc-1) fusion protein, containing ten tandem repeats, was made and used to immunize C3H/HeOuj mice, which supposedly have a high incidence of breast cancer. C3H/HeOuj mice were injected eight times with 5 microg oxidized mannan muc-1-glutathione-S-transferase (MMFP) with or without cyclophosphamide, which is used to increase cellular immunity. At 80 age weeks, only 12.1% (4 of 33) mice of the untreated C3H/HeOuj mice had mammary tumors. The reason for the low incidence of breast cancer in these mice is not known, but all the mammary tumors were MUC-1+ breast adenocarcinomas and were transplantable to C3H/HeOuj mice. The incidence was 11.4% (4 of 35) in mice injected with MMFP: 38.2% (13 of 34) in mice given cyclophosphamide; and 14.3% (2 of 14) in mice treated with glutathione-S-transferase. That is, cyclophosphamide increased the incidence of mammary tumors, and metastases were found in only these mice. Fewer tumors (6 of 34 or 17.6% compared with 13 of 34 or 38.2% with cyclophosphamide only) occurred in the group immunized with MMFP and cyclophosphamide. Mice immunized with MMFP had high levels of muc-1 antibodies and cellular immune responses (the frequency of the precursor of the cytotoxic Tlymphocyte cell was 1 of 40,000 to 1 of 100,000), which were not found in control groups. The occurrence of muc-1 immunity, particularly the presence of large amounts of anti-mucin-1 antibodies, had no effect on tumor incidence. Thus, the immunization with murine muc-1 reduced the tumor incidence in only cyclophosphamide-treated mice and led to strong muc-1 antibody production and to cellular responses. These findings have implications for human tumor immunotherapy in which strong antibody and weak cellular responses are to be expected and, indeed, have been found.
Xing
P X
PX
The Austin Research Institute, Austin and Repatriation Medical Center, Heidelberg, Victoria, Australia.
Poulos
G
G
McKenzie
I F
IF
D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D007111:Immunity, Cellular; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016233:Immunotherapy, Active; D015994:Incidence; D007274:Injections, Intraperitoneal; D008325:Mammary Neoplasms, Experimental / Q000453:epidemiology / Q000276:immunology* / Q000378:metabolism / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D018396:Mucin-1 / Q000008:administration & dosage / Q000276:immunology*; D009368:Neoplasm Transplantation; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology*
D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; C116055:MUC1 tandem repeat peptide; D018396:Mucin-1; D010446:Peptide Fragments; D003520:Cyclophosphamide